Anti-Rat VEGF - Biotin
| Code | Size | Price |
|---|
| LEI-V160-50ug | 50 ug | £762.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Caprine (Goat)
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Rat
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Western Blot (WB)
Shipping:
Ambient
Storage:
The lyophilized biotinylated antigen affinity purified polyclonal antibody can be stored desiccated at -20°C to -70°C for up to twelve months from date of receipt. The reconstituted biotin conjugate can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted conjugate aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. No detectable loss of activity was observed after six months.
Further Information
Conjugate/Tag/Label:
Biotin
Format:
This biotinylated antigen affinity purified polyclonal antibody has been 0.2 um filtered and lyophilized from modified Dulbecco?s phosphate buffered saline (1X PBS) pH 7.2 ? 7.3 containing 50 ug of bovine serum albumin per ug of antibody with no calcium, magnesium, or preservatives present.
Formulation:
This biotinylated antigen affinity purified polyclonal antibody has been 0.2 um filtered and lyophilized from modified Dulbecco?s phosphate buffered saline (1X PBS) pH 7.2 ? 7.3 containing 50 ug of bovine serum albumin per ug of antibody with no calcium, magnesium, or preservatives present.
Immunogen:
Purified Recombinant Rat VEGF (Accession # AAL07526)
Long Description:
Vascular endothelial growth factor (VEGF), a potent proangiogenic cytokine1 is the key signal used by oxygen-hungry cells to promote growth of blood vessels. It binds to specialized receptors on the surfaces of endothelial cells and directs them to build new vessels.2 VEGF are crucial regulators of vascular development during embryogenesis (vasculogenesis) and blood-vessel formation in the adult (angiogenesis). Abnormal VEGF function is associated with inflammatory diseases including atherosclerosis, and hyperthyroidism.3,4,5,6
NCBI Gene:
83785
Target:
VEGF
References
1. Folkman, J. et al. (2008) FASEB J. 22: 3728
2. Goodsell, DS. et al. (2002) The Oncologist 7: 569
3. Mugishima, H. et al. (2006) J Atheroscler Thromb. 13: 130
4. Claesson-Welsh, L. et al. (2006) Exp Cell Res. 312: 549
5. Claesson-Welsh, L. et al. (1999) Trends Biochem Sci. 28: 488
6. Ellis, LM. et al. (2005) J Clin Oncol. 23: 1011
Related Products
| Product Name | Product Code | Supplier | Anti-Human VEGF | LEI-V100 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-Human VEGF (Clone 26503) | LEI-V103 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Mouse VEGF | LEI-V104 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human VEGF - Biotin | LEI-V105 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Mouse VEGF - Biotin | LEI-V106 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Rat VEGF (Clone 123704) | LEI-V142 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Rat VEGF | LEI-V149 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||